Recombinant Extracellular Matrix Protein Fragments Support Human Embryonic Stem Cell Chondrogenesis

Aixin Cheng, MD, PhD,1,*,# Stuart A. Cain, PhD,1,* Pinyuan Tian, PhD,1 Andrew K. Baldwin, PhD,2 Paweena Uppanan, MSc, Cay M. Kielty, PhD,1 and Susan J. Kimber, PhD1

We previously developed a 14-day culture protocol under potentially GMP, chemically defined conditions, to generate chondroprogenitors from human embryonic stem cells (hESCs). In vivo work has confirmed the cartilage repair capacity of these cells in a nude rat osteochondral defect model. Aiming to enhance hESC-chondrogenesis, we screened a range of extracellular matrix (ECM) molecules for their ability to support differentiation of hESCs toward chondrocytes. We identified two novel ECM protein fragments that supported hESC-chondrogenesis: Fibronectin III (fibronectin 7–14 protein fragments, including the RGD domain, syndecan-binding domain, and heparin-binding domain) and fibrillin-1 (FBN1) fragment PF8 (encoded by exons 30–38, residues 1238–1605, which contains the RGD motif but not heparin-binding site). These two protein fragments support hESC-chondrogenesis compared with the substrates routinely used previously (a mixture of fibronectin and gelatin) in our directed chondrogenic protocol. We have identified recombinant fibronectin fragment (FN III) and FBN1 fragment (PF8) as alternative coating substrates to promote expression of genes known to regulate chondrocytes and code for chondrocyte ECM components. These recombinant protein fragments are likely to have better batch to batch stability than full-length molecules, especially where extracted from tissue/serum.

Keywords: cartilage repair, extracellular matrix, protein fragments, fibronectin, embryonic stem cells

Introduction

The articular cartilage covering of synovial joints disperses loading forces to the underlying subchondral bone and provides a low-friction interface to facilitate joint movement. After the closure of the growth plate, the articular cartilage loses regenerative capacity due to the lack of blood supply.1 Chondrocytes, the only cell type in cartilage, have a low proliferation rate and produce all the extracellular matrix (ECM) in the cartilage, mainly proteoglycans and other noncollagenous molecules in adult cartilage, as turnover of the type II collagen network is very slow.2 These characteristics contribute to a lack of self-repair capacity in the event of disease or trauma, when the integrity of cartilage is disrupted.3

Chondrocytes maintain healthy cartilage and are embedded in the ECM, which contains a number of ECM components. For example, collagen II and collagen XI fibers4,7 and proteoglycans with 80% by weight of the tissue being fluid.8 Additional components include a collection of other molecules, such as link protein, COMP, matrilins, decorin, and hyaluronic acid, which act as bridging molecules and by binding to collagens regulate the fibrillogenesis and assembly of the cartilage network.8–11 Aggrecan is the major cartilage-specific proteoglycan core protein to which glycosaminoglycan (GAG) chains, predominantly chondroitin sulfate and keratan sulfate, are attached forming a ternary complex with link protein and hyaluronan.13–16 and aggrecan also binds to collagens.17

The pericellular matrix, the region adjacent to the chondrocytes, has a specialized composition, including collagens and proteoglycans,18,19 but also fibronectin (FN) and fibrillin1.20 Both interact with collagens, but their location suggests that they are available for interaction with chondrocytes. As far as its role in collagen fibrillogenesis,21,22 FN has been shown to stimulate chondrocyte GAG formation in vitro,23 and has well-established growth factor interactions.24 Fibrillin-1 microfibrils are also deposited in the cartilage ECM after adolescence and mutations cause skeletal abnormalities such as overgrowth of long bones.20
β1-integrin adhesion molecules are the main ECM receptors for collagens and FN. The functional integrin dimers formed by the alpha and beta transmembrane subunits regulate multiple biological processes such as proliferation, migration, survival, and differentiation, including human embryonic stem cells (hESCs).\textsuperscript{25,26} Collagens interact with cells through α1-, α2-, α3-, and α10β1 receptors and α5β1 binds to FN.\textsuperscript{27} Specifically, α5β1 is required for normal development of the cartilaginous growth plates.\textsuperscript{28} While αVβ6 is a receptor for fibrillin-1\textsuperscript{29} and contains TGFβ-binding protein-like modules.\textsuperscript{30}

We previously reported a directed differentiation protocol (DDP) for hESCs, which mimics the natural development process toward hyaline cartilage to generate chondrogenic cells.\textsuperscript{31} This protocol exploits the feeder-free and serum-free culture system we developed to provide potential GMP conditions for the growth and expansion of hESCs.\textsuperscript{20} We have shown that hESC-chondrocytes can generate hyaline-like cartilage repair in a nude rat osteochondral-defect model.\textsuperscript{32} Previously, cells have been differentiated on plasma FN in combination with gelatin. In this study, we used this chemically defined chondrogenic differentiation protocol to screen an array of recombinant ECM molecules and protein fragments, including some found in cartilage, for support of hESC-chondrogenesis. We found FN and fibrillin-1 recombinant fragments support hESC-chondrogenesis in a manner equivalent to full-length FN.

**Methods**

**Generation and purification of ECM peptide**

All noncommercial protein fragments were expressed in mammalian 293-EBNA cells and modified with either N or C terminal His-tags. FN fragment FN III (residues 1176-2082) was cloned from RNA extracted from ARPE-19 cells and was modified with an N-terminal His6 tag (Fig. 1A). Full-length human FN was cloned from mesenchymal stromal cell (MSC) RNA and had a sequence matching *Homo sapiens* fibronectin 1 (FN1). Transcript variant X9 (XM_005246406.1). This variant contains all FN domains apart from domain EDB (Fig. 1A). The native FN signal sequence was replaced by the BM40 signal peptide and a His6 tag. Recombinant human fibrillin-1 fragments (PF1, PF2, PF8, PF9, PF17-1) and fibrillin-2 fragment (PF17-2) were modified with an N-terminal His6 tag.\textsuperscript{33–35} (Fig. 1B). ADAMTS6 full length is encoded by residues 22-1117, and ADAMTS6 C-terminal region starts at the 1st TSR domain and is encoded by residues 558-1117 modified, with a C-terminal His6 and V5 tag.\textsuperscript{36} Syndecan-4 ectodomain encoded by residues 19-143 (ESI...IFE)\textsuperscript{37} and syndecan 2 ectodomain encoded by residues 19-141 (ESR...LKF) were expressed with a C-terminal His6 tag. LTB-P1 was expressed with a C-terminal His6 tag.\textsuperscript{37} Agrin fragments were cloned from RNA extracted from ARPE-19 cells, Agrin K6-SEA (residues 535-1252) and Agrin ST2-LGL3 (residues 1304-2064) were modified with an N-terminal His6 tag. All proteins were purified using immobilized metal ion affinity chromatography (IMAC) (HisTrap FF GE Healthcare), under high salt conditions (0.5 M NaCl).

Fibrillin-1, syndecan-4, and LTB-P1 fragments were further purified using size-exclusion chromatography (Superdex 200 or Superose 6, GE Healthcare). Purity of recombinant proteins was analyzed using SDS-PAGE with Coomassie blue, and protein concentrations were calculated using BCA Protein Assay (Pierce) (Fig. 1C). Full amino acid sequences and expected molecular masses of recombinant protein fragments FN III and PF8, and recombinant full-length FN are shown in Supplementary Figure S1 (Supplementary Data are available online at www.liebertpub.com/tea).

**Preparation of ECM matrix assay plates**

A 96-well plate coated with ECM molecules containing, in duplicate, a range of concentrations (1, 10, 25 μg/mL) fragments of fibrillin-1, fibrillin-2, and agrin as well as cellular and plasma FN was created as previously described.\textsuperscript{38} The plate also contained single concentration of the following ECM proteins: LTB-P1 C-terminal fragment, MAGP-1, syndecan-2 extracellular domain, syndecan-4 extracellular domain, and fibrillin-1. ECM proteins diluted in 80 μL PBS were incubated overnight on 96-well clear black plates (Greiner #655090) at 4°C. The supernatant was removed, and wells were blocked by the addition of 10 mg/mL bovine serum albumin (BSA) for 1 h. BSA solution was removed, and the plates were stored at −80°C before use. BSA-coated and uncoated tissue culture plate (TCP) wells were used as controls (Supplementary Table S1).

**Quantification of adhered ECM proteins**

To compare the relative quantities of absorbed protein fragments on the tissue culture plastic surface, a modified BCA protein assay was performed (Pierce\textsuperscript{38} BCA Protein Assay Kit, 23225). Protein fragments were incubated on 96-well tissue culture plastic plates in triplicate overnight at concentrations of 5, 10, and 25 μg/mL. The plates were then washed with PBS, before the absorbed protein was resolubilized from the surface using 50 μL of 4 M Guanidine-HCL for 1 h. Two hundred microliters of BCA working reagent was then added and left to develop for 20 min. Absorbance was measured at 570 nm, and background absorbance was subtracted (PBS only) (Supplementary Fig. S2).

**Cell culture and directed chondrogenic differentiation**

MAN6 and MAN7 cells were cultured, as previously described.\textsuperscript{39} In brief, hESCs were cultured on mitomycin C-inactivated mouse embryonic fibroblasts (iMEFs) in hESC-medium. For feeder-free culture, cells were lifted from the iMEF layers with TrypLE, (Thermo Fisher Scientific) and plated onto plasma FN-coated (Millipore, lot 2594323, 2854203) (Supplementary Fig. S3) tissue culture flasks with mTeSR™1 medium (STEMCELL technology). The hESCs were differentiated with sequential addition of growth factors, as previously described.\textsuperscript{39} In brief, Wnt3a, Activin-A, and BMP2 were applied to differentiate hESCs to primitive streak–mesendoderm (day 1–3), followed by addition of BMP4, follistatin, and GDF5 to differentiate to mesoderm (day 4–8), finally, GDF5 with FGF2 was used to direct chondrogenesis (day 9–14).

**Screen novel ECM molecules/protein fragments supporting hESCs chondrogenesis**

hESCs undergoing chondrogenic directed differentiation were seeded onto 96-well TCPs coated with a range of ECM proteins or protein fragments at day 8 of the protocol as \(3 \times 10^4\) cells/cm². Cells were further cultured in chondrogenic medium as described.\textsuperscript{32} On day 14 of the protocol,
cells were fixed using 4% paraformaldehyde followed by Safranin O staining (0.1% Safranin O, 5 min).

**Gene expression analysis**

Total RNA was extracted using an RNaseasy® Kit (Qiagen) and DNA removed using Ambion® DNase I (Thermo Scientific). Total RNA was reverse transcribed using M-MLV reverse transcriptase (Promega). Expression of candidate genes was determined using SYBR Green PCR Master Mix (Applied Biosystems) with a CFX96/384 Touch™ Real-Time PCR Detection System (Bio-Rad) using gene-specific oligonucleotide primers (Supplementary Table S2). Expression levels were normalized to K GAPDH and calculated using

**FIG. 1.** Schematic diagram of protein fragments. (A) Schematic diagram of the domain structure of full-length human fibronectin (FN FL) and fibronectin type III 7 to 14 (FN III) fragment, which contains the RGD-cell binding site and the heparin binding site. (B) Domain organization of the recombinant fibrillin-1 fragment PF8 compared with full-length fibrillin-1. (C) SDS-PAGE of full-length human fibronectin (FN FL), FN III 7-14 fragment, and fibrillin-1 fragment PF8 run under nonreducing and reducing conditions. Full amino acid sequences and expected molecular masses of FN III, PF8, and recombinant full-length FN are shown in the Supplementary Figure S1. Color images available online at www.liebertpub.com/tea
the $2^{-\Delta Ct}$ method. At least three independent differentiation experiments were performed.

**Flow cytometry**

Single-cell suspensions were fixed in ice-cold methanol (10 min at $-20^\circ$C) and permeabilized by incubation with 1% BSA, 0.5% Triton-X-100 in PBS for 15 min. Cells were incubated with primary antibody (Rabbit mAb anti-SOX9, Cell-Signaling Technology 94794; rabbit anti-Collagen II, 10 μg/mL, Novus NB100-91715) diluted in ice-cold blocking buffer (1% BSA in PBS) overnight at 4°C followed by appropriate secondary antibodies. Flow cytometry was conducted using a BD Biosciences Fortessa, and the software Diva gating was used for analysis. FSC-H plotted against FSC-A and a gate drawn around the single cells. This gate was applied to a plot of FSC-A against SSC-A, and then, another gate was drawn around the cells, excluding the debris. The combination of these two gates was applied to the histogram of the fluorescence measurement.

**Cell lysate and western blotting**

Cells were washed with cold PBS and lysed in RIPA buffer (Thermo Fisher Scientific 89900) with protease inhibitor cocktail (Roche, 0589297001) for 10 min on ice, followed by centrifugation at 14,000 g at 4°C for 15 min. The supernatant was saved, 20 μg of protein was resolved by 10% SDS-PAGE gel electrophoresis and transferred to a PVDF membrane blocked with 5% low-fat milk in TBST for 1 hr followed by primary antibodies (mouse anti-SOX9, 1 μg/mL, Abcam 76997; rabbit anti-Collagen II, 10 μg/mL, Novus NB100-91715). The membrane was washed three times with PBST and incubated in IRDye 800CM (LI-COR) secondary antibody for 1 hr at room temperature. It was washed with PBST and scanned with the Odyssey® CLx Imaging System.

**FIG. 2.** Screening ECM molecules/peptides supporting hESC-chondrogenesis. On day 8 of DDP, $5 \times 10^4$ cells/cm² were seeded on 96-well plates coated with a variety of ECM molecules and further cultured for 6 days in chondrogenic medium. On day 14, cells were fixed and stained with Safranin O (A), (for substrate abbreviations shown in Fig. 2A see Supplementary Table S1), and the staining intensity was quantified with ImageJ (B). (C) Recombinant full-length fibronectin (Fn-full), fibronectin fragment (FN III), fibrillin-1 fragment PF8, and plasma fibronectin (pFN) were plated at increasing concentrations onto a 96-well plate ($n=4$). Day 8 DDP chondroprogenitors were seeded and cultured until day 14, then stained with Safranin O. The Area of Safranin O staining was quantified and plotted against concentration (D). Nonlinear regression was performed using GraphPad Prism using [Agonist] versus response—Variable slope equation parameters. DDP, directed differentiation protocol; ECM, extracellular matrix; hESC, human embryonic stem cell. Asterisks indicate $P$ values where *$P \leq 0.05$; **$P \leq 0.01$; ***$P \leq 0.001$. Color images available online at www.liebertpub.com/tea.
Phalloidin staining

Cells cultured on different coating substrates were fixed using 4% paraformaldehyde for 10 min at room temperature, then quenched and permeabilized, using 0.2 M Glycine 0.5% Triton x-100. Phalloidin–Atto 565 (Sigma, 94072) staining was performed for 20 min following the manufacturer’s instructions and then washed with PBS followed by nuclear staining with DAPI (Thermo Scientific D1306) for 5 min. Images on six-well plates collected on a Leica TCS SP5 AOBS upright confocal using a 20×/0.50 HCX Apo L dipping objective. Images on 96-well plates were collected using CellInsight™ CX5 High-Content Screening Platform (Thermo Fisher Scientific). Images were then processed and analyzed using Fiji ImageJ (http://imagej.net/Fiji/Downloads). The area covered by the cells for each field of view was calculated by adjusting the threshold to include only the phalloidin stained cells; this gives an indication of the number of cells attached and the amount of cell spreading and was expressed as a% of the total image area. To quantitate the cell area, phalloidin- and DAPI-stained images were processed using CellProfiler V2.2.40. A pipeline was used that identified the positions of the DAPI-stained nuclei, this information was used to identify individual cells on the phalloidin-stained images. The MeasureObjectSizeShape module then calculated cell area and morphology information.

Statistics

Data are shown as the mean±SEM. An unpaired t test for data from two groups or one-way ANOVA for data from groups of three or more was used to compare data. p values <0.05 were considered to be significant.

Results

Screening of ECM proteins/protein fragments supporting hESC-chondrogenesis

To screen ECM components that support hESC-chondrogenesis, a range of ECM proteins and protein fragments was coated onto 96-well TCPs (Fig. 2, Supplementary Table S1). The plates were initially tested for attachment of human MSCs, to ensure sufficient functional protein coating, MSCs were found to adhere and cover a significantly larger cell area, on wells containing FN (cellular and plasma) and on the fibrillin-1 fragments containing the RGD motif (PF17 and PF8) (Supplementary Fig. S4) than on other substrates. An identical plate was then used to screen hESC chondroprogenitors starting at day 8 of the DDP. Cells were seeded at 5×10⁴ cells/cm² and cultured in chondrogenic medium (containing BMP2, GDF5, and FGF2) for 6 days with medium changed daily. On day 14, cells were fixed and stained with Safranin O to identify GAG formation indicative of chondrogenesis (Fig. 2A). The relative intensity of Safranin O staining was quantified across the plate using ImageJ (Fig. 2B).

Full-length FN and PF8 (Fig. 1) reproducibly supported generation of Safranin O-positive chondrogenic cells, as did FN fragment FNIII (for structure refer to Fig. 1A) tested separately. We therefore decided to focus on these three molecules for testing further their ability to support hESCs chondrogenesis. To identify the optimal concentration of substrate, increasing concentrations of FN-full, FNIII, PF8, and plasma FN were coated onto a 96-well plate. Day 8 hESC chondroprogenitors were cultured until day 14, as above mentioned, and stained with Safranin O (Fig. 2C). FN full, FNIII, and PF8 all reach Safranin O saturation at 10 mg/mL, and so, this concentration was chosen for future experiments. The EC50 for

FIG. 3. Recombinant ECM supporting pluripotency and hESCs chondrogenesis. Recombinant full-length FN (rFN), FN fragment (FNIII), and Fibrillin 1 fragment PF8 were tested for supporting pluripotency of MAN7 cells along with plasma FN (pFN) and vitronectin (Vitro). Recombinant FN full length and PF8 maintained pluripotency of MAN7 hESCs after 2 passages (A). Fibronectin rFN, FN III, and PF8 were compared with a mixture of plasma FN and gelatin for supporting hESC-chondrogenesis in MAN6 and MAN7 cell lines; qRT-PCR was used to quantify chondrogenic marker genes (B). Three runs for each cell lines were performed and representative results are shown. Asterisks indicate P values where *P ≤ 0.05; **P ≤ 0.01; NS, non significant.
Plasma FN mixture (Gel/FN) was used for further experiments. chondrogenic staining in these experiments, and so, Gelatin/and FN full 7.1 significant extent on any of the substrates (data not shown).

**Support for hESC-chondrogenesis by identified ECM molecules**

We then tested whether these three substrates could support the culture of the starting hESCs and found that recombinant full-length FN and PF8 support cell adhesion, culture expansion, and maintenance of pluripotent MAN7 cells for two passages, based on gene expression of pluripotency-associated markers to the same extent as plasma FN or vitronectin, used routinely in the laboratory. However, the FNIII fragment did not even support hESC adhesion and was therefore excluded from the hESC qRT-PCR analysis (Fig. 3A).

Next, we evaluated the hESC-chondrogenesis at the transcript level, by applying these substrates from day 8 to day 13 of our DDP with two lines, MAN6 and MAN7. Gene expression analysis showed that even though there was a small variation between the different cell lines, PF8 and FNIII support hESC-chondrogenesis. Compared to 50:50 plasma FN and gelatin used previously, on recombinant full-length FN, the cells expressed equivalent SOX9, COL2A1, and COL11A1, but higher ACAN and BGN. The protein fragments produced similar results, although the increase in ACAN tended to be lower, especially for MAN6 (Fig. 3B). However, RUNX2 express was also higher within cells cultured on full-length FN, FNIII, and PF8 in this line. COL10A1 was not expressed to any significant extent on any of the substrates (data not shown).

**PF8 and FNIII support hESCs chondrogenesis through maintaining SOX9 expression and GAG deposition**

To explore further what underlies the support of PF8 and FNIII protein fragments for hESC-chondrogenesis, we performed western blot analysis for SOX9 protein in cells cultured on the different substrates. We found that using FNIII and PF8 as coating substrate, the expression level of SOX9 was similar as that in the cells cultured on the mixture of FN and gelatin (Fig. 4A, B). To further confirm the protein levels for SOX9 and Collagen II in the cells cultured on different substrates, we performed flow cytometry and found that the expression level of SOX9 and collagen II proteins was very similar in the cells cultured on all of FNIII, PF8, and FN full length, confirming that they can support hESCs chondrogenesis (Fig. 4C). More detailed assessment and quantitation of Safranin O staining also indicated that PF8, FNIII, and recombinant FN substrates have the potential to promote equivalent or greater deposition of GAG in differentiating chondrogenic cell aggregates compared with the mixture of FN and gelatin. So, these substrates appear to be able to support hESC-chondrocytes ECM deposition (Fig. 5).

To check that there was no significant differences in the amounts of recombinant protein on the tissue culture plastic surface, when applied at 10μg/mL for the four protein substrates used, the absorption of each protein/protein fragment was also quantified and no significant difference was found, although the amount of protein from FN:gelatin coatings was higher (Supplementary Fig. S2).

**FIG. 4.** SOX9 protein level in hESCs during chondrogenesis on different coating substrates. MAN7 hESCs were induced to undergo directed chondrogenic differentiation, on day 8, different coating substrates were applied and cells were cultured in chondrogenic medium to day 13. The cell lysates were collected for western blotting to investigate the expression of SOX9. Three independent runs were performed and representative results are shown (A), and the quantification of results from three runs are shown, normalized to the ratio between SOX9 and GAPDH on day 0. Statistical analysis was carried out using GraphPad Prism using 1-way ANOVA and Tukey’s multiple comparison test. Asterisks indicate p values where *p ≤ 0.05; **p ≤ 0.01. (B) Flow cytometry analysis of SOX9 and collagen II level in hESC-chondrogenic cells on different coating substrates. MAN7 hESCs were induced to undergo directed chondrogenic differentiation, on day 8, different coating substrates were applied and cells were cultured in chondrogenic medium to day 13. The cells were fixed and assessed by flow cytometry using antibodies against SOX9 and Collagen II and Alexa Fluor® 488 secondary antibody (C). Color images available online at www.liebertpub.com/tea

**Effect of Different Coating Substrates on the Assembly of F-actin**

The chondrocyte cytoskeleton includes actin microfilaments, microtubules, and vimentin-intermediated filaments, and F-actin is cortical in location. This contrasts with its location in fibroblastic cells and MSCs. We performed
from phalloidin staining at 24 h after plating on Day 8, to investigate the distribution of f-actin and found that there was no difference in the distribution of the f-actin on the different substrates, both cortical actin and prominent stress fibers were observed (Fig. 6A). On pFN and PF8, there were significantly fewer cells attached even at higher concentrations of substrate (Fig. 6B and Supplementary Fig. S5), and total cell area was significantly lower for pFN and PF8 at the saturated concentration of 10 \( \mu \text{g/mL} \) (Figs. 2C and 6C). On PF8 and pFN, cells were less spread indicated by a lower average cell area (Fig. 6D). By day 14, the cytoskeleton had altered, with a loss of stress fibers, and an increase in cortical actin, although no difference was seen between substrates (Fig. 6E). Collagen II deposition could also be detected.

**Discussion**

In this study, we exploited our directed hESCs chondrogenic differentiation protocol, mimicking development, to screen a variety of 2D coating substrates. Our aim was to find a substrate which could support chondrogenesis to the same extent or better than the plasma FN/gelatin combination used previously. An ideal substrate could be produced as a recombinant protein, in a cost-effective and reproducible manner avoiding batch-to-batch variation. We produced an array of recombinant extracellular proteins and protein fragments, including FN and fibrillin-1 fragments, which were screened for hESC culture expansion and for generation of Safranin O positive cells in the DDP to generate chondroprogenitors.

Compared with the previously used plasma FN and gelatin mixture, full-length recombinant FN, fibronectin fragment (FNIII), and fibrillin-1 fragment (PF8) (Fig. 1.) could all support adhesion and differentiation of the hESCs-chondroprogenitors (Figs. 2 and 5). Adding FN to the medium has been shown to promote MSC chondrogenesis, and we have shown that plasma FN supports the early stages of hESC-chondrogenesis. In this study, we have demonstrated that the FNIII fragment also promotes hESC-chondrogenesis in the later stages of our 2D protocol. Fibrillin-1 (FBN1) is present as a loose meshwork of fibers within cartilage matrix by 20 weeks of fetal gestation and then accumulates in the pericellular matrix forming broad banded fibers by later adolescence. Therefore, we propose that FBN1 may promote the maturation of hESC chondroprogenitors. Both these protein fragments contain RGD domains, which provide the binding motif for cell surface receptor integrins. When other FBN fragments that contained homologous EGF repeats, but non-RGD-containing TB (TGF\( \beta \)-binding protein-like) domains were used, they did not support cell attachment or chondrogenesis in the initial screen for chondroprogenitors and MSC attachment (Fig. 2 and Supplementary Fig. S4). Similar results for cell attachment of induced pluripotent stem cells to only the RGD-containing protein fragments were seen with an identical 96-well protein array.

It has been shown that interaction of human articular chondrocytes with RGD-containing protein fragments not only initiates cell attachment but also promotes cell migration, proliferation, and maintenance of the chondrogenic phenotype. So the RGD domain in FNIII and PF8 may function beyond mere adhesion in supporting hESCs chondrogenesis. Indeed, chondrocyte attachment to FN occurs through expression of the major integrin receptor for FN, \( \alpha 5\beta 1 \) which interacts with the RGD domain. Notably, \( \beta 1 \) mediated ECM interaction is reduced in osteoarthritis. It has been suggested that FN–integrin interaction may play a role in chondrocyte survival and retention in the cartilage niche. Enrichment of the pericellular matrix with FN and its integrin engagement could also contribute to the mechanosensing and mechanoregulation of the chondrocyte.

Previously, we used plasma FN as coating substrates in our differentiation protocol and the batch variation sometimes...
hindered the reproducibility of the differentiation protocol. The recombinant FN and fibrillin-1 fragment provide more reliable coating substrates for hESCs, which can in future be made under GMP conditions for translational application. Despite some slight variation between the two lines tested in the expression of SOX9, collagen II, and collagen XI, the expression of aggrecan and biglycan transcripts were enhanced by using FNIII and PF8 (Fig. 3). It has been shown that biglycan interacts strongly with collagen type II, but not with type I

in vitro. The enhanced expression of aggrecan and biglycan may indicate that FNIII and PF8 have the capacity to promote cartilage ECM production. The strong Safranin O staining also indicates that FNIII and full-length FN promoted the deposition of GAGs during hESC-chondrogenesis compared with the mixture of plasma FN and gelatin, while plasma FN only supported chondrogenesis in a variable manner. So the transition from FN and gelatin to FNIII or PF8 may be beneficial to promote ECM deposition as well as synthesis.

FIG. 6. Imaging of the actin cytoskeleton. Recombinant full-length fibronectin (FN-full), fibronectin fragment (FN III), fibrillin-1 fragment PF8, and plasma fibronectin (pFN) were incubated at increasing concentrations on a 96-well plate (n = 4). Day 8 DDP chondroprogenitors were seeded and cultured for 24 h. (A) Adherent cells were visualized with phalloidin and DAPI stains, insert contains expanded region. Images are from 10 µg/mL of substrate. Scale bar: 100 µm. (B) The average area of phalloidin staining per field of view for increasing concentrations of substrate. (C) The average area of phalloidin staining per field of view and (D) average cell area at 10 µg/mL of substrate were calculated using ImageJ and CellProfiler, respectively. A montage of the images taken and CellProfiler cell identification is shown in Supplementary Figure S5. Statistical analysis was carried out using GraphPad Prism using 1-way ANOVA and Tukey’s multiple comparison test. Asterisks indicate p values, where *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001. (E) Day 8 DDP chondroprogenitors were seeded onto different substrates on six-well plates. Day 14 cells were visualized by confocal microscopy using phalloidin (red) and DAPI (Blue) stains. Collagen II (green) was visualized using a mouse anticollagen II antibody (2B1.5, ab185430; Abcam). Insert contains expanded region. Scale bar: 100 µm. Color images available online at www.liebertpub.com/tea.
SOX9 is the master transcription factor regulating chondrogenesis; if protein fragments can promote the expression of this transcription factor, there is a strong likelihood of their supporting chondrogenesis. Actin polymerization and filament formation has been shown to negatively regulate the transcriptional activity of SOX9 and induce chondrocyte dedifferentiation, in which chondrocytes lose chondrogenic gene expression and cell morphology changes from round to fibroblast-like. As FN regulates assembly of actin filaments in fibroblasts through the RGD domain and C-terminal heparin-binding region, we also investigated the effect of different substrates on F-actin assembly. After 24 h seeding on different coating substrates from Day 8, staining with phalloidin revealed significant cell spreading, but interestingly, fewer hESC-chondrogenic cells attached on PF8 and these were less spread, with a smaller cell area (Fig. 6). However, by day 14, the differences in the chondrogenic cell staining using Safranin O was not as prominent. Moreover, by day 14, imaging of the actin cytoskeleton revealed that it had been remodeled to be mainly cortical in distribution (Fig. 6). As the relaxation of f-actin can potentially restrict the spreading of hESC-chondrogenic cells, it could be beneficial to promoting their differentiation as shown for chondrocytes.

When chondrocytes become elongated with flattened and elongated actin stress fibers, they decrease synthesis of type II collagen and aggrecan, but increase type I collagen synthesis, thus, dedifferentiating to a fibroblast-like phenotype. On the contrary, if chondrocytes are induced to become rounded, the chondrocyte phenotype is rescued. Taking this together, we propose that FNIII and PF8 may contribute to the promotion of hESC-chondrogenesis through triggering or allowing the remodeling of actin assembly to that more conducive to chondrogenesis.

Our study has demonstrated that the recombinant ECM molecules, FN and its fragment FN III as well as the fibrillin-1 fragment PF8 can replace the mixture of plasma FN and gelatin as optimal coating substrates for hESC-chondrogenesis. As the quality of these recombinant ECM molecules is more reliable than plasma FN, their use will increase the reproducibility of hESC chondrogenic differentiation. Since these substrates can be made under GMP conditions, they are well placed to be used for clinical application of chondrogenic cells for transplantation. Furthermore, the facilitation of cortical actin distribution by these substrates is conducive with a chondrocyte phenotype, and the role of particular protein fragments in this warrants further investigation. Better understanding of the role of the matrix in mesenchymal condensation, formation of the endochondral skeleton, and chondrocyte development to form the permanent cartilage may bring advantages in dissecting the causes of aberrant cartilage and bone formation in chondrodysplasias as well as in generation of chondrocytes for cell therapy.

Acknowledgments

This work was funded by the UK Regenerative Medicine Platform hub grant MR/K026666/1. We thank Mr Michael Jackson for FACS support. The Faculty of Biology Medicine and Health Bioimaging Facility microscopes were funded by the Biotechnology and Biological Sciences Research Council (BBSRC), the Wellcome Trust and the University of Manchester Strategic Fund. PU acknowledges funding from the Royal Thai government.

Disclosure Statement

No competing financial interests exist.

References


Address correspondence to:
Susan J. Kimber, PhD
Faculty of Biology, Medicine and Health
University of Manchester
Michael Smith Building
Oxford Road
Manchester M13 9PT
United Kingdom

E-mail: sue.kimber@manchester.ac.uk

Received: June 7, 2017
Accepted: December 19, 2017
Online Publication Date: February 7, 2018